A pivotal Phase 3 trial of lucerastat, an oral therapy for Fabry disease, produced promising results pointing to clinical benefit in the rare lysosomal storage disorder, according to a new trial report. The data suggest lucerastat may address disease manifestations not fully treated by current standards, though full dataset details and regulatory plans were not included in the brief. The positive readout could prompt regulatory engagement and partnership or commercial strategy discussions for an oral option in the Fabry space.